Vaccination against Lyme borreliosis

References

• Gross D M, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy Z A, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703–706
   PubMed Web of Science ®Google Scholar
• Dickman S. Possible cause found for Lyme arthritis. Science 1998; 281: 631–632
   PubMedGoogle Scholar
• Dorner F, Barrett P N. Vaccine technology: looking to the future. Ann Med 1999; 31: 51–60
   PubMed Web of Science ®Google Scholar
• Wormser G P. A vaccine against Lyme disease?. Ann Intern Med 1995; 123: 627–629
   PubMedGoogle Scholar
• Wormser G P. Immunization against Lyme disease - an important first step. N Engl J Med 1998; 339: 263–271
   PubMedGoogle Scholar
• Wormser G P. Vaccination as a modality to prevent Lyme disease. Infect Dis Clin North Am 1999; 13: 135–138
   PubMedGoogle Scholar
• Lim L C, England D M, Duchateau B, Glowacki N, Schell R. Borrelia burgdorferi-specific T lymphocytes induce severe destructive Lyme arthritis. Infect Immun 1995; 63: 1400–1408
   PubMedGoogle Scholar
• Schwan T G, Piesman J, Golde W T, Dolan M C, Rosa P A. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Set USA 1995; 92: 2909–2913
   PubMed Web of Science ®Google Scholar
• Batsford S, Rust C, Neubert U. Analysis of antibody response to the outer surface protein family in Lyme borreliosis patients. J Infect Dis 1998; 178: 1676–1683
   PubMedGoogle Scholar
• Meurice F, Parenti D, Fu D, Krause D S. Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine. Clin Infect Dis 1997; 25: S71–5, Suppl 1
   PubMedGoogle Scholar
• Steere A C, Sikand V K, Meurice F, Parenti D L, Fikrig E, Schoen R T, et al. Vaccination against Lyme disease with recombinant borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998; 339: 209–215
   PubMed Web of Science ®Google Scholar
• Marwick C. Guarded endorsement for Lyme disease vaccine. JAMA 1998; 279: 1937–1938
   PubMedGoogle Scholar
• LYMErix prescribing information. Smith, Kline & Beecham Pharmaceuticals. Philadelphia, PA December, 1998
   Google Scholar
• Keller D, Koster F, Marks D, Hosbach P, Erdile L, Mays J P. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994; 271: 1764–1768
   PubMedGoogle Scholar
• Sigal L H, Zahradnik J M, Lavin P, Patella S J, Bryant G, Haselby R, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer surface protein A to prevent Lyme disease. N Engl J Med 1998; 339: 216–222
   PubMed Web of Science ®Google Scholar
• Zhong W, Gern L, Stehle T, Museteanu C, Kramer M, Wallich R, et al. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Eur J Immunol 1999; 29: 946–957
   PubMedGoogle Scholar
• Livey I, Mitterer A, Tauer C, Mundt W, Langer W, Schober-Bendixen S, et al (1998) OspC vaccine candidate. Abstracts of the Symposium on the Pathogenesis and Management of Tick-borne Diseases, ViennaAustria, Sept, 28–301998, 24
   Google Scholar
• Eder G, Barrett N, Crowe B, Gerencer M, Livey I, Dorner F (1998) Design and preliminary data of OspC vaccine candidate: clinical trials. Abstracts of the Symposium on the Pathogenesis and Management of Tick-borne Diseases, ViennaAustria, Sept, 28–301998, 27
   Google Scholar
• Hanson M S, Cassatt D R, Guo B P, Patel N K, McCarthy M P, Dorward D W, et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun 1998; 66: 2143–2153
   PubMed Web of Science ®Google Scholar
• Guo B P, Brown E L, Dorward D W, Rosenberg L C, Hook M. Decorin-binding adhesins from Borrelia burgdorferi. Mol Microbiol 1998; 30: 711–723
   PubMedGoogle Scholar
• Carlsson S-A, Granlund H, Nyman D, Wahlberg P. IgG seroprevalence of Lyme borreliosis in the population of the Åland Islands in Finland. Scand J Infect Dis 1998; 30: 501–503
   PubMedGoogle Scholar